Pharmacy & Drug Pricing
Expert articles and analysis related to pharmacy & drug pricing.
AI Summary — Last 24 Hours
Medicaid drug-pricing experimentation is back in focus as Louisiana’s hepatitis C subscription-based payment model appears to have produced stronger impact than Washington’s, underscoring that “Netflix-style” purchasing depends heavily on benefit design, outreach, correctional-health linkage, and Medicaid policy execution—not just the rebate contract itself ([Open Minds](https://news.google.com/rss/articles/CBMimwJBVV95cUxONkJhUjNwcUYxRF9jdWFQVUoySFYxV2pUTkFjTW5yNHBvVVlMVW5uaHJpMTUtYWxzYnJMVW92MXNTc1diS1VnSVlPZERHOUxLN3JvQTk5R0hHeDR3TVJFRFFhbXdIdjczdEI3ZjRDdjZiS1NoLXpkeks1OFU0d3NkWWJ5UEdLRFMtMDlDVmhjdGNCZC1wYkJPb25ITG8yTE9HanF4eFB0a2d0ZGx3RlNQaktyWjZEaWNhaVd2aWhjY2lxSFk2WHNQeVA1aVRCXzVLckZtVldpUHM3RGZQQ091OFptWnJwYm1GSFNuZmhFN24wX01
Related Articles
Medicaid Subscription-Based Payment Models For Hep C Drugs In Louisiana & Washington State Had A Larger Impact In Louisiana Due To Policy Factors - open minds
Medicaid Subscription-Based Payment Models For Hep C Drugs In Louisiana & Washington State Had A Larger Impact In Louisiana Due To Policy Factors  open minds
Medicare Ends Part D Premium Subsidy Program - open minds
Medicare Ends Part D Premium Subsidy Program  open minds
FDA Approves New Type Of Medication For ADHD - open minds
FDA Approves New Type Of Medication For ADHDÂ Â open minds
Novel therapies for von Willebrand disease | Blood Advances | American Society of Hematology - ashpublications.org
Novel therapies for von Willebrand disease | Blood Advances | American Society of Hematology  ashpublications.org